GlassScriptPhysician profile
Andrew Greenspan
NPI 1649262742
$9,039.26
in general payments reported to CMS, 2019-2025
57 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,220 · 2020: $202 · 2021: $169 · 2022: $924 · 2023: $2,010 · 2024: $1,670 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,207 · Long Term Medical Supply Or Device Loan: $299 · Education: $18.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,206.52 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $18.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,384.60 | 2019-2025 | Piqray, Kisqali |
| Pfizer INC. | $1,060.08 | 2019-2025 | |
| Janssen Biotech, INC. | $660.32 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $485.90 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $433.65 | 2019-2025 | Enhertu, Lynparza |
| Amgen INC. | $430.66 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $405.84 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $403.07 | 2022-2025 | Padcev, Xospata, Xtandi |
| Genzyme Corporation | $328.58 | 2019-2024 | |
| Seagen INC. | $291.45 | 2019-2023 | Padcev, Adcetris |
| Celgene Corporation | $270.22 | 2019-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $262.38 | 2019-2025 | Tecentriq, Venclexta, Phesgo |
| E.R. Squibb & Sons, L.L.C. | $243.41 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $221.75 | 2019-2025 | |
| Eisai INC. | $212.04 | 2019-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Greenspan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.